

REMARKS**Support for the amendments**

The amendment to the specification reconciles the § 120 priority claim with the filing papers and § 1.63 declaration in this application and updates the status for the other listed applications. The title and abstract are revised to correspond to the claimed subject matter.

The references in the claims to residues 23 to 128 of SEQ ID NO: 4 and residues 20 to 140 of SEQ ID NO: 6 are supported by the disclosure as filed. The figures as filed identify the predicted signal peptide cleavage sites as recited in the amended claims. The disclosure as filed conveys to the skilled worker that cleavage of the propeptides as indicated is expected in the expression systems of the invention. The claims recite the portions of SEQ ID NOs: 4 and 6 corresponding to positions +1 to +107 of the light chain variable region and positions +1 to +113 of the heavy chain variable region as shown in Figures 4 and 5, respectively.

Support for “immunologically active” anti-CD20 antibodies is found, *e.g.*, at page 13, lines 12-16; and for “chimeric” antibodies, *e.g.*, at page 12, line 27. The recitation of kappa light chain and gamma 1 heavy chain constant regions is found, *e.g.*, at page 20, lines 9-10; page 21, lines 13-14; and line 17. Support for the recitation of the host cells in claims 70-75 is found, *e.g.*, at page 24, lines 1-2; page 24, lines 6 and 15; and page 42, lines 13-14.

The method for expressing and purifying anti-CD20 antibody as claimed in claim 76 is supported, *e.g.*, at page 19, line 22 to page 20, line 5; page 24, lines 1-26; page 42, line 28 to page 43, line 5. The recitation of “pharmaceutical carrier” and “pharmaceutically acceptable buffer” in claims 77, 78, 82, and 84 is supported, *e.g.*, at page 14, paragraph bridging to 15.

The claims to methods of using antibodies are supported generally, *e.g.*, at page 9, lines 10-17. Particular limitations in such claims have exemplary support in the specification as follows. Antibodies “not conjugated to a toxin or radioisotope” are supported, *e.g.*, at page 12, line 9. The recitation of “human light chain constant region and a human gamma 1 heavy chain constant region” is supported, *e.g.*, at page 20, lines 9-10 and page 21, lines 13-14 and 17.

Therapeutically effective dosages from 100 mg/m² to 500 mg/m² are described, *e.g.*, at page 57, lines 4-9. Applicant notes that this dosage range would cover at least the administration of fixed-dose formulations containing, *e.g.*, about 200 to about 900 mg of antibody for most patients.¹

Treatment over a period of about 2 to 10 weeks is supported, *e.g.*, at page 16, lines 10-15. The specific treatment of claim 92 is described, *e.g.*, at page 57, line 27 to page 58, line 1. Depletion of peripheral B cells in excess of 2 weeks is supported, *e.g.*, at page 57, lines 1-2. Antibodies having the specificity of murine monoclonal antibody 2B8 as recited in claims 86 and 93 are described, *e.g.*, at page 43, lines 8-9 and page 43, lines 10 and 16-20. The ATCC deposit of the 2B8 hybridoma is cited at page 62, lines 16-29.

Treatments comprising the administration of chemotherapeutic agents are described, *e.g.*, at page 61, lines 22-28. The agents recited in claim 96 are identified, *e.g.*, at page 62, line 1. The recitation of treating relapsed B cell lymphoma in claim 97 is supported, *e.g.*, at page 56, line 17.

The amendments at pages 16 and 26 correct obvious informalities and identify trademarked names.

The amendments add no new matter to the disclosure.

Drawing correction

A substitute sheet for Figure 5 is attached. The correction involves the rectification of a typographical error in the amino acid sequence of the heavy chain variable domain of chimeric antibody C2B8. In particular, the predicted translation is corrected to indicate that the residue at position +14 is Pro, not Ala.

The nucleotide sequence in the figure as filed is correct. The codon corresponding to position +14 (CCT) in fact encodes the amino acid proline (Pro), not alanine (Ala) as shown in the figure. This is evidenced by the attached table showing the amino acids encoded by DNA

¹ Based on conversions from mg/m² to mg dosages for an "average" 70 kg, 67 inch human.

codons, copied from the textbook by Lodish *et al.*, *Molecular Cell Biology*, available online at the PubMed website at the U.S. National Library of Medicine. (Note that this table lists U instead of T, reflecting the codons employed in RNA sequences.)

The correction is supported by the present application as filed and by the evidence in the priority applications. The following evidence supports the correctness of the nucleotide sequence and the assignment of residue +14 of the heavy chain at Pro instead of Ala.

- First, Figure 3, which provides the complete nucleotide sequence of the TCAE-8 vector, shows the same nucleotide sequence as Figure 5 in the region of interest. A copy of the relevant part of that figure from U.S. Patent No. 5,736,137 with the CCT codon boxed is attached.
- Second, the nucleotide sequence shown in the original sequence listing as SEQ ID NO: 3 (now SEQ ID NO: 5 in this application) is correct. The sequence listing was present in the application as filed.
- Third, the corresponding Fig. 5 from the original application in this series, U.S. application serial no. 07/978,891, shows the same nucleotide sequence and the correct predicted amino acid sequence (*i.e.*, including a Pro residue at position +14). The '891 application is incorporated by reference into this application. A copy of the figure from that application indicating residue +14 is also attached.
- Finally, the undersigned states that he has reviewed information, believed to be correct, indicating that the nucleotide sequence in the deposited clone, ATCC 69119, does in fact encode a Pro residue at position +14 of the heavy chain.

The error in Figure 5 of the application as filed is an "obvious error" that can be properly corrected on the evidence of record. Because the CCT codon always encodes a Pro amino acid residue, the skilled worker would immediately recognize that an error was present. Importantly, the skilled worker would also immediately understand what the correction must be. Also, the evidence in the patent application and in the priority document fully supports correcting the figure to show a Pro residue at position +14 in the amino acid sequence.

Corrected sequence listing

A substitute sequence listing accompanies this paper. The sequence listing is revised to reflect the correction to the amino acid sequence shown in Figure 5 (SEQ ID NO: 6) as discussed immediately above. Except for this correction, the sequences in the new sequence listing are identical to the sequences in the application as filed. For the reasons discussed in connection with the correction of the figure, applicant submits that this amendment adds no new matter.

A computer-readable copy of the attached sequence listing is filed with this amendment on compact disc. In compliance with 37 C.F.R. § 1.821(e), the undersigned states that the paper and computer-readable copies of the sequence listing are identical.

Conclusion

Applicant believes that this application is in condition for examination and requests that the examiner prepare an action on the merits at an early date.

Respectfully submitted,



David L. Fitzgerald, Reg. No. 47,347
Attorney for Biogen Idec Inc.

22 August 2005

SIDLEY AUSTIN BROWN & WOOD LLP
1501 K Street, N.W.
Washington, DC 20005

tel. (202) 736-8818
fax (202) 736-8711

MOLECULAR CELL BIOLOGY

Lodish Berk Zipursky Matsudaira Baltimore Darnell

W H FREEMAN AND COMPANY

Short Contents Full Contents

Other books @ NOBI

BEST AVAILABLE COPY

Molecular Cell Biology → 4. Nucleic Acids, the Genetic Code, and the Synthesis of Macromolecules → 4.4. The Three Roles of RNA in Protein Synthesis

Table 4-2. The Genetic Code (RNA to Amino Acids)*

First Position (5' end)	Second Position			Third Position (3' end)
	U	C	A	G
U	Phe Phe Leu Leu	Ser Ser Ser Ser	Tyr Tyr Stop (och) Stop (amb)	Cys Cys Stop Trp
C	Leu Leu Leu (Met)	Pro Pro Pro	His His Gln	Arg Arg Arg
A	Ile Ile Ile Met (start)	Thr Thr Thr Thr	Asn Asn Lys Lys	Ser Ser Arg Arg
G	Val Val Val (Met)	Ala Ala Ala	Asp Asp Glu	Gly Gly Gly

*"Stop (och)" stands for the ochre termination triplet, and "Stop (amb)" for the amber, named after the bacterial strains in which they were identical.

Navigation

About this book

- 4. Nucleic Acids, the Genetic Code, and the Synthesis of Macromolecules
- 4.1. Structure of Nucleic Acids
- 4.2. Synthesis of Biopolymers: Rules of Macromolecular Carpentry
- 4.3. Nucleic Acid Synthesis
- 4.4. The Three Roles of RNA in Protein Synthesis
- 4.5. Stepwise Formation of Proteins on Ribosomes
- PERSPECTIVES for the Future
- PERSPECTIVES in the Literature
- Testing Yourself on the Concepts
- MCAT/GRE-Style Questions

ANNOTATED SHEET

HUMAN KAPPA CONSTANT=324bp=107 AMINO ACID & STOP CODON
CTCCAATCGG GTAACCTCCA GGAGAGTGT ACAGAGCAGG ACAGCAAGGA CAGCACCTAC 1560
AGCCTCAGCA GCACCCTGAC GCTGAACAAA GCAGACTACG AGAAACACAA AGTCTACGCC 1620
TGGGAAGTCA CCCATCAGGG CCTGAGCTCC CCCGTCACAA AGAGCTTCAA CAGGGGAGAG 1680
STOP
LIGHT
CHAIN|Eco RI LINKER #4=81bp
TGTTCATTTC AGATCCGTTA ACGGTACCA ACTACCTAGA CTGGATTCTG GACAACATCC 1740
1646 7
GGCCGTGATA TCTACGTATG ATCAGCCTCG ACTGTGCTTT CTAGTTGCCA GCCATCTGTT 1800
1771 2
GTTTGCCCTT CCCCCGTGCC TCCCTTGACC CTGGAAGGTG CCACTCCAC TGTCCTTTC 1860
TAATAAAATG AGGAAATTGC ATCCATTGT CTGAGTAGGT GTCATTCTAT TCTGGGGGGT 1920
BOVINE GROWTH HORMONE POLYADENYLATION REGION=231bp
GGGGTGGGGC AGGACAGCAA GGGGAGGAT TGGGAGACA ATAGCAGGCA TGCTGGGGAT 1980
GGGTGGGGCT CTATGGAACC AGCTGGGGCT CGACAGCTAT GCCAAGTACG CCCCCTATTG 2040
2002 3 2017 8
ACGTCAATGA CGGTAAATGG CCGGCTGGC ATTATGCCA GTACATGACC TTATGGGACT 2100
TTCCTACTTG GCAGTACATC TACGTATTAG TCATCGCTAT TACCATCGTG ATGCGGTTTT 2160
CMV PROMOTER-ENHANCER=334bp
GGCAGTACAT CAATGGGCGT GGATAGCGGT TGAAGTACG GCGATTTC AAGTCTCCAC 2220
CCATTGACGT CAATGGGAGT TTGTTTTGGC ACCAAAATCA ACGGGACTTT CCAAATGTC 2280
GTAAACAATC CGCCCCATTG ACCCAAATGG GCGGTACCG TGTACGGTGG GAGGTCTATA 2340
LINKER #6=7bp Sal I
TAAGCAGAGC TGGGTACCTC CTCACATTCA GTGATCAGCA CTGAACACAG ACCCGTCGAC 2400
2351 2 2358 9
START
HEAVY CHAIN SYNTHETIC & NATURAL LEADER Mlu I 2457 8
ATGGTTGGA GCCTCATCTT GCTCTTCTT GTGGCTTTTG CTACCGGTCT CCGTCCAG 2460
2401 -5 -4 -3 -2 -1 +1
GTACAACTGC AGCAGCCTGG GGCTGAGCTG GTGAAGCTG GGGCCTCAGT GAAGATGTCC 2520
TGCAAGGCTT CTGGCTACAC ATTTACCACT TACAATATGC ACTGGGTAAA ACAGACACCT 2580
HEAVY CHAIN VARIABLE=363bp=121 AMINO ACID
GGTCGGGGCC TGGAAATGCAT TGGAGCTATT TATCCCGGAA ATGGTGATAC TTCCTACAAT 2640
CAGAAGTTCA AAGGCAAGGC CACATTGACT GCAGACAAAT CCTCCAGCAC AGCCTACATG 2700
CAGCTCAGCA GCCTGACATC TGAGGACTCT GCGGTCTATT ACTGTGCAAG ATCGACTTAC 2760
TACGSCGGTG ACTGGTACTT CAATGTCTGG GGGCAGGGA CCACGGTCAC CGTCTCTGCA 2820
Nhe I
GCTAGCACCA AGGGCCCATC GGTCTTCCCC CTGGCACCCT CCTCCAAGAG CACCTCTGGG 2880
GGCACAGCGG CCCTGGGCTG CCTGGTCAAG GACTACTTCC CCGAACCGGT GACGGTGTGG 2940
HUMAN GAMMA 1 CONSTANT=993bp
TGGAATCAG GCGCCCTGAC CAGCGGCGTG CACACCTTCC CGGCTGTCTT ACAGTCCTCA 3000

FIG. 3B

BEST AVAILABLE COPY

ANNOTATED SHEET

978891

mHvy

FIGURE 5

5

Leader

Frame 1

-19	-15	-10	-5
Met Gly Trp Ser Leu Ile Leu Leu Phe Leu Val Ala Val Ala Thr Arg Val			
ATG GGT TGG AGC CTC ATC TTG CTC TTC CTT GTC GCT GTT GCT ACG CGT GTC			
2409	2418	2427	2436 2445

-1	+1	FR1	10	15
Leu Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala Ser				
CTG TCC CAG GTA CAA CTG CAG CAG CCT GGG GCT GAG CTG GTG AAG CCT GGG GCC TCA				
2460	2469	2478	2487 2496	2505

20	25	30	31	CDR1	35	36
Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Asn Met His Trp						
GTG AAG ATG TCC TGC AAG GCT TCT GGC TAC ACA TTT ACC AGT TAC AAT ATG CAC TGG						
2517	2526	2535	2544	2553	2562	

40	FR2	45	49	50	52	52A	53	54
Val Lys Gln Thr Pro Gly Arg Gly Leu Glu Trp Ile Gly Ala Ile Tyr Pro Gly Asn								
GTA AAA CAG ACA CCT GGT CGG GGC CTG GAA TGG ATT GGA GCT ATT TAT CCC GGA AAT								
2574	2583	2592	2601	2610	2619			

55	CDR2	60	65	66	FR3	70
Gly Asp Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys						
GGT GAT ACT TCC TAC AAT CAG AAG TTC AAA GGC AAG GCC ACA TTG ACT GCA GAC AAA						
2631	2640	2649	2658	2667	2676	

75	80	82	82A	82B	82C	83	85
Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val							
TCC TCC AGC ACA GCC TAC ATG CAG CTC AGC AGC CTG ACA TCT GAG GAC TCT GCG GTC							
2688	2697	2706	2715	2724	2733		

90	94	95	CDR3	100	100A	100B	100C	100D	101	102	103
Tyr Tyr Cys Ala Arg Ser Thr Tyr Tyr Gly Gly Asp Trp Tyr Phe Asn Val Trp Gly											
TAT TAC TGT GCA AGA TCG ACT TAC TAC GGC CGT GAC TGG TAC TTC AAT GTC TGG GGC											
2745	2754	2763	2772	2781	2790						

105	FR4	110	113
Ala Gly Thr Thr Val Thr Val Ser Ala			
GCA GGG ACC ACG GTC ACC GTC TCT GCA			
2802	2811	2820	

50

COPYRIGHT 1992 by Mitchell E. Reff, La Jolla, CA

BEST AVAILABLE COPY